Pharmacokinetics of azithromycin in serum and sinus fluid after administration of extended-release and immediate-release formulations in patients with acute bacterial sinusitis.
Author(s): Ehnhage A, Rautiainen M, Fang AF, Sanchez SP
Affiliation(s): Department of Clinical Science, Intervention and Technology, Division of Otorhinolaryngology, Karolinska Institutet, and Nacka Narsjukhus Proxima AB, Stockholm, Sweden. jadelinia@hbase.com
Publication date & source: 2008-06, Int J Antimicrob Agents., 31(6):561-6. Epub 2008 May 5.
Publication type: Comparative Study; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
As high drug levels at the infection site are desirable for optimal activity, this study explored whether one dose of azithromycin extended release (AZ-ER) achieved higher azithromycin exposure in sinus fluid than azithromycin immediate release (AZ-IR) in adults with acute bacterial sinusitis. Subjects received AZ-ER (2g single dose; n=5) or AZ-IR (500mg daily for 3 days; n=4) and blood and sinus aspirates were collected until 120 h after initial dosing. Within 24 h, exposure was four- and three-fold higher with AZ-ER than with AZ-IR in serum and sinus fluid, respectively. Sinus fluid exposure was five- and three-fold higher than serum for AZ-IR and AZ-ER, respectively. Azithromycin concentrations in sinus fluid were maintained up to 120 h.
|